CD4 and cancer: Although the beneficial effects of HAART have been already observed in patients with a CD4+ T-cell count greater than 200 cells/mm3, or greater than or equal to 350 cells/mm3, developing counties, including Asia and Africa, need to understand other important factors [e.g. economic factors, side effects or serious non AIDS events (ANAEs) like cancer and cardiovascular disease].